Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America
Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America
复制标题
DOI：
10.1093/clinids/23.5.1171
复制
发表时间：
1996-11-01
影响因子：
11.8
通讯作者：
Kain, KC
中科院分区：
文献类型：
--
作者：
Phillips, EJ;Keystone, JS;Kain, KC
人们怀疑新大陆存在耐氯喹的间日疟原虫疟疾，但尚未得到证实。我们报告了南美洲圭亚那三例感染间日疟疾的患者的病例，尽管其血液浓度达到治疗水平，但标准氯喹治疗（25 mg/kg）仍失败。耐氯喹的间日疟原虫的最佳治疗尚不清楚，但最近的研究表明，氯喹（25 mg/kg）和高剂量伯氨喹（48 小时内 2.5 mg/kg）的组合是有效的治疗方法，我们的两名患者复发了接受这种组合的直接观察治疗后 6-8 周，这些病例证实了圭亚那存在耐氯喹的间日疟原虫，并强调需要更好的治疗耐氯喹和伯氨喹的间日疟原虫的方案。
The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed. We report the cases of three patients who acquired vivax malaria in Guyana, South America, and for whom standard chloroquine therapy (25 mg/kg) failed despite therapeutic blood levels, The optimal treatment of chloroquine-resistant P. vivax malaria is unknown, but recent studies suggest that a combination of chloroquine (25 mg/kg) and high-dose primaquine (2.5 mg/kg over 48 hours) is effective therapy, Two of our patients had recurrences of P. vivax malaria 6-8 weeks after receiving directly observed therapy with this combination, These cases confirm the presence of chloroquine-resistant P. vivax in Guyana and emphasize the need for better treatment regimens for chloroquine-resistant and primaquine-resistant P. vivax malaria.